Jungjong Cho

Vice President at Kolon Life Science, Inc.

Presenter

Kolon Life Science is a public South Korean biotech company, subsidiary of Kolon Group. Kolon Life science has been committed to research and development of innovative cell and gene therapies since its establishment in 2000. Kolon Life Science specializes in research and development of viral vector-based gene therapies focusing on treatment of neurological disorders and cancer. Our pipeline includes KLS-2031, a clinical-stage AAV-based gene therapy for treatment of neuropathic pain, as well as KLS-3021, a preclinical-stage vaccinia-based oncolytic virus for treatment of solid tumors. As we continue our pursuit in advancing our technology in viral vector platforms, we are actively involved in open innovation for promising technologies and innovative ideas. We aim to grow as a global forefront biotech through successful development and commercialization of our next generation medicines to ultimately improve human health and quality of life.